Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 19/20 | 0.65 |
| ▸ | SLC5A1 | P13866 | 15/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13483184 | 0.85 | SLC5A2 (0.66) | SLC5A2SLC5A1 | |
| SCHEMBL2577571 | 0.84 | SLC5A2 (0.77) | SLC5A2SLC5A1EPHX2 | |
| SCHEMBL5382129 | 0.82 | SLC5A2 (0.72) | SLC5A2SLC5A1 | |
| SCHEMBL14120458 | 0.75 | POLB (0.67) | SLC5A2SLC5A1EPHX2 | |
| SCHEMBL29193242 | 0.74 | SLC5A2 (0.60) | SLC5A2SLC5A1EPHX2 | |
| SCHEMBL5383602 | 0.73 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL2580816 | 0.72 | SLC5A2 (0.68) | SLC5A2SLC5A1 | |
| SCHEMBL2575321 | 0.72 | SLC5A2 (0.78) | SLC5A2SLC5A1 | |
| SCHEMBL2577336 | 0.71 | SLC5A2 (1.00) | SLC5A2SLC5A1EPHX2 | |
| SCHEMBL4350700 | 0.71 | SLC5A2 (1.00) | SLC5A2SLC5A1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655633-B2 | Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-7655633-B2 | Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |